Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Uterine fibroid embolization reduces fibroid-related urinary symptoms

Uterine fibroid embolization—an interventional radiology treatment for the noncancerous yet very common growths that develop in the muscular wall of the uterus—improves a number of women's lower urinary tract problems that are specifically caused by those fibroids, confirm researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

Prostate cancer updates

A Hunter-based prostate cancer support group says ground-breaking research by the University of Newcastle will help save many lives in the region. This new work has found patients with localized advanced prostate cancer can double their chances of survival by undertaking hormone therapy in combination with radiology treatment. This comes from a 10 year trial, coordinated by the University's Professor Jim Debnam.

28 Mar 2011

Inflammatory bowel disease in children - Delays in diagnosis common

Once a medical rarity in children, inflammatory bowel disease today is increasingly common in kids, but many of them may not be diagnosed in a timely manner, according to experts from the Pediatric Inflammatory Bowel Disease Center at Johns Hopkins Children’s Center.

28 Mar 2011

CBAI partners with BlueCross and offers cord blood banking services to their members

Cord Blood America, Inc., announced today it has entered into an agreement with BlueCross BlueShield of Tennessee and is now offering the storage of umbilical cord blood at a discount rate as consistent with its other BCBS licensee contracts.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

XTL announces MinoGuard acquisition

XTL announced on March 24, 2011, it entered into a term sheet to acquire the activity of MinoGuard Ltd. by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process.

25 Mar 2011

Inadequate nutrition linked to greater risk of anemia in postmenopausal women

A new study published in the April 2011 issue of the Journal of the American Dietetic Association indicates that inadequate nutrition is linked to a greater risk of anemia in postmenopausal women.

25 Mar 2011

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced multiple posters on peginesatide have been accepted for presentation at the National Kidney Foundation 2011 Spring Clinical Meeting taking place April 26-30, 2011 in Las Vegas, Nevada.

24 Mar 2011

New insights into cancer genome may lead to designer drugs for myeloma

Patients with myeloma could benefit from ‘designer’ drugs in the future after new genome-mapping technology has allowed scientists to identify a full genetic blueprint of the mutations which drive the bone marrow cancer.

23 Mar 2011

Xenon founder receives Canada Wightman Award for leadership in medical science

Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada.

23 Mar 2011

Iron deficiency during pregnancy may impact child's brain development

A mother's iron deficiency early in pregnancy may have a profound and long-lasting effect on the brain development of the child, even if the lack of iron is not enough to cause severe anemia, according to a University of Rochester Medical Center study published in the scientific journal PLoS One.

23 Mar 2011

Oncologists to discuss treatment of blood cancer in elderly

Top oncologists are meeting in Rome today to discuss the treatment of blood cancer in the elderly, with the aim of driving widespread change to ensure equality of care for everyone, whatever their chronological age.

19 Mar 2011

Medicare officials signal no payment changes on anemia drugs

Medicare officials signaled Wednesday that they will not change a payment policy for biotech drugs made by Amgen and Johnson & Johnson when they are used to treat anemia in kidney disease patients, despite data suggesting heart risks for those patients.

18 Mar 2011

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

18 Mar 2011

Global settlement agreement reached in Tuschl patents litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.

16 Mar 2011

Extra intake of iron may not benefit pregnant women, except when anemic

Although universal prenatal supplementation with iron is recommended, an extra intake of iron does not noticeably benefit pregnant women, except when they are anemic. This was observed by researchers of the Institute of Tropical Medicine Antwerp and colleagues who followed more than a thousand pregnant women in Burkina Faso.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

Iron deficiency during pregnancy may directly impact infant breathing health

Need a reason to take your iron supplements? Iron deficiency during pregnancy may directly impact infant and childhood breathing health according to a study recently published in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

10 Mar 2011

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011.

9 Mar 2011